Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
The drug, called ISRIB, has already been shown in laboratory studies to restore memory function months after traumatic brain injury (TBI), reverse cognitive impairments in Down Syndrome, prevent noise-related hearing loss, fight certain types of prostate cancer, and even enhance cognition in healthy animals.
Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University, who found that increased doses of cisplatin were associated with increased hearing loss.